伊立替康联合5-氟尿嘧啶/亚叶酸钙治疗晚期大肠癌的临床观察

目的:观察伊立替康(CPT-11)联合5-氟尿嘧啶(5-FU)与亚叶酸钙(CF)治疗晚期大肠癌的临床疗效和不良反应.方法:24例晚期大肠癌患者采用CPT-11 180 mg/m2,化疗第一天ivgtt 90 min;CF 100 mg/d,ivgtt,d1～5;5-FU 500 mg/m2,ivgtt,d1～5,21 d为1周期,治疗2个周期以上评价疗效.结果:24例均可评价疗效,CR 0例,PR 9例,NC 7例,PD 8例,有效率(CR PR)37.5%.中位疾病进展时间(TTP)6.7个月.不良反应主要为迟发性腹泻、中性粒细胞减少及乙酰胆碱综合征.结论:CPT-11联合5-Fu/CF治疗晚期大肠癌疗效肯定,安全性好,不良反应可耐受.可使大部分患者临床获益.

Irinotecan combined with 5-Fu/CF in the treatment of advanced colorectal cancer

Objective:To evaluate the efficacy and toxicity of irinotecan(CPT-11) combined with 5-Fu/CF in the treatment of advanced colorectal cancer.Methods:24 patients with advanced colorectal cancer were treated with irinotecan 180 mg/m2,ivgtt,the first day;CF 100 mg/d,ivgtt,for 1~5 days;5-Fu 500 mg/m2,ivgtt,for 1~5 days,and repeated every 3 weeks.The efficacy was evaluated after two cycles.Results:In 24 evaluable patients,The total effective rate was 37.5% in the 24 patients with advanced colorectal cancer,CR was 0;PR was 9;NC was 7;PD was 8.TTP was 6.7 months.The common treatment related adverse events were delayed diarrhea and neutropenia and cholinergic syndrome.Conclusion:CPT-11 combined with 5-Fu/CF for treating patients with advanced colorectal cancer is an active regimen;Its side effects are tolerable and it makes most patients benefit clinically.